+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Minireview: From the bench, toward the clinic: therapeutic opportunities for cannabinoid receptor modulation



Minireview: From the bench, toward the clinic: therapeutic opportunities for cannabinoid receptor modulation



Molecular Endocrinology 29(6): 801-813



The effects of cannabinoids have been known for centuries and over the past several decades two G protein-coupled receptors, CB1 and CB2, that are responsible for their activity have been identified. Endogenous lipid-derived cannabinergic agents have been found, biosynthetic and catabolic machinery has been characterized, and synthetic agents have been designed to modulate these receptors. Selective agents including agonists, antagonists, inverse agonists, and novel allosteric modulators targeting either CB1 or CB2 have been developed to inhibit or augment their basal tone. As a result, the role these receptors play in human physiology and their potential therapeutic applications in disease states are being elucidated. The CB1 receptor, although ubiquitous, is densely expressed in the brain, and CB2 is largely found on cells of immune origin. This minireview highlights the role of CB1 in excitotoxic assaults in the brain and its potential to limit addiction liability. In addition, it will examine the relationship between receptor activity and stimulation of insulin release from pancreatic β-cells, insulin resistance, and feeding behavior leading toward obesity. The roles of CB2 in the neuropathology of amyotrophic lateral sclerosis and in the central manifestations of chronic HIV infection potentially converge at inflammatory cell activation, thereby providing an opportunity for intervention. Last, CB2 modulation is discussed in the context of an experimental model of postmenopausal osteoporosis. Achieving exquisite receptor selectivity and elucidating the mechanisms underlying receptor inhibition and activation will be essential for the development of the next generation of cannabinergic-based therapeutic agents.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 058321529

Download citation: RISBibTeXText

PMID: 25866875

DOI: 10.1210/me.2015-1062


Related references

Modulation of CB1 cannabinoid receptor by allosteric ligands: Pharmacology and therapeutic opportunities. Neuropharmacology 124: 3-12, 2017

Therapeutic modulation of cannabinoid lipid signaling: metabolic profiling of a novel antinociceptive cannabinoid-2 receptor agonist. Life Sciences 92(8-9): 482-491, 2013

Functionally selective cannabinoid receptor signalling: therapeutic implications and opportunities. Biochemical Pharmacology 80(1): 1-12, 2010

The role of erythropoietin and its receptor in growth, survival and therapeutic response of human tumor cells From clinic to bench - a critical review. Biochimica et Biophysica Acta 1806(1): 82-95, 2010

Cannabinoid Modulation of Memory Consolidation in Rats: Beyond the Role of Cannabinoid Receptor Subtype 1. Frontiers in Pharmacology 8: 200-200, 2017

Neurobiological insights and novel therapeutic opportunities for CNS disorders from mGlu receptor allosteric and biased modulation. Current Opinion in Pharmacology 32(): 49-55, 2016

Identification of a functionally relevant cannabinoid receptor on mouse spleen cells that is involved in cannabinoid-mediated immune modulation. Molecular Pharmacology 42(5): 736-742, 1992

Localization of cannabinoid receptors and nonsaturable high-density cannabinoid binding sites in peripheral tissues of the rat: implications for receptor-mediated immune modulation by cannabinoids. Journal of Pharmacology and Experimental Therapeutics 268(3): 1612-1623, 1994

Conceptual changes in cancer chemotherapy--biochemical modulation of 5-FU from bench to clinic. Gan to Kagaku Ryoho. Cancer & ChemoTherapy 27 Suppl 2: 193-205, 2000

Therapeutic antibodies and derivatives: from the bench to the clinic. Current Pharmaceutical Biotechnology 9(6): 421-422, 2009

Asthma heterogeneity and therapeutic options from the clinic to the bench. Current Opinion in Allergy and Clinical Immunology 12(1): 60-67, 2012

From bench to clinic with apoptosis-based therapeutic agents. Nature 407(6805): 810-816, 2000

The Dopamine and Cannabinoid Interaction in the Modulation of Emotions and Cognition: Assessing the Role of Cannabinoid CB1 Receptor in Neurons Expressing Dopamine D1 Receptors. Frontiers in Behavioral Neuroscience 5: 49-49, 2011

Peginterferon Lambda-1a, a New Therapeutic for Hepatitis C Infection, from Bench to Clinic. Journal of Clinical and Translational Hepatology 1(2): 116-124, 2013

Opportunities for Translation from the Bench: Therapeutic Intervention of the JAK/STAT Pathway in Neuroinflammatory Diseases. Critical Reviews in Immunology 35(6): 505-527, 2015